HanAll Biopharma Reports Q1 2024 Financial Results and Provides Business Update

HanAll Biopharma achieved 18.4 percent revenue growth in the first quarter compared to the same period last year, recording a revenue of 34.1 billion Korean Won, driven by continued strong sales across key products.

Scroll to Top